{"id":"saxagliptin-onglyza","safety":{"commonSideEffects":[{"rate":"7-8","effect":"Nasopharyngitis"},{"rate":"4-5","effect":"Urinary tract infection"},{"rate":"6-7","effect":"Headache"},{"rate":"5-6","effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By blocking DPP-4, saxagliptin prevents the degradation of GLP-1 and GIP, incretin hormones that stimulate glucose-dependent insulin release and suppress glucagon secretion. This mechanism lowers postprandial and fasting blood glucose levels in patients with type 2 diabetes without causing hypoglycemia when used as monotherapy, since insulin secretion is glucose-dependent.","oneSentence":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:53.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07363863","phase":"","title":"Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03-01","conditions":"Rectal Carcinoma","enrollment":100},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT05768945","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-30","conditions":"Diabetes","enrollment":742670},{"nctId":"NCT07194876","phase":"","title":"Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-12-01","conditions":"Cesarean Section, Maternal Health","enrollment":770},{"nctId":"NCT07188545","phase":"","title":"Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2025-09-15","conditions":"Cardiovascular Kidney Metabolic Syndrome","enrollment":23280000},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT04735042","phase":"","title":"SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-10-07","conditions":"Type 2 Diabetes, Urinary Tract Infections","enrollment":60},{"nctId":"NCT07033585","phase":"PHASE2, PHASE3","title":"Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-06-15","conditions":"Type 2 Diabetes","enrollment":600},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT05160974","phase":"","title":"QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-12-30","conditions":"Type 2 Diabetes Mellitus","enrollment":679},{"nctId":"NCT04445714","phase":"PHASE4","title":"To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-07","conditions":"Type 2 Diabetes Mellitus","enrollment":196},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT06099067","phase":"","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-15","conditions":"Type 2 Diabetes Mellitus","enrollment":239990},{"nctId":"NCT02285985","phase":"PHASE4","title":"Effects of Saxagliptin on Adipose Tissue Inflammation in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-02","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":103},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT03936023","phase":"","title":"Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-09-22","conditions":"Diabetes","enrollment":182126},{"nctId":"NCT05870462","phase":"PHASE4","title":"Semaglutide and Vascular Regeneration","status":"UNKNOWN","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2023-04-29","conditions":"Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT01267448","phase":"PHASE4","title":"Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2014-09-09","conditions":"Diabetes Mellitus Type 2, Hyperglycemia","enrollment":100},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT03660683","phase":"PHASE4","title":"Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Sabyasachi Sen","startDate":"2018-10-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":15},{"nctId":"NCT01527747","phase":"PHASE4","title":"Effects of DPP-4 Inhibition on Triglycerides","status":"SUSPENDED","sponsor":"Oregon Health and Science University","startDate":"2012-01","conditions":"Type 2 Diabetes, Hypertriglyceridemia","enrollment":15},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03714594","phase":"PHASE2","title":"Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2018-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT02597101","phase":"PHASE2","title":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes","status":"COMPLETED","sponsor":"Nick Giannoukakis, PhD","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":14},{"nctId":"NCT02407899","phase":"PHASE4","title":"Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes","status":"COMPLETED","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2015-03","conditions":"Diabetes Mellitus, Type 1","enrollment":300},{"nctId":"NCT04796428","phase":"PHASE4","title":"GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial","status":"UNKNOWN","sponsor":"Center for Outcomes Research and Clinical Epidemiology, Italy","startDate":"2021-06-30","conditions":"Diabetes Mellitus, Type 2","enrollment":1167},{"nctId":"NCT02377388","phase":"PHASE3","title":"DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-02-07","conditions":"Platelet Aggregation During Acute Myocardial Infarction","enrollment":74},{"nctId":"NCT04521049","phase":"PHASE4","title":"Tubular Markers in Response to Saxagliptin Therapy","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT02419612","phase":"PHASE3","title":"A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-14","conditions":"Diabetes","enrollment":444},{"nctId":"NCT02481479","phase":"PHASE4","title":"Saxagliptin and Cardiac Structure and Function","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2015-06","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Heart Failure","enrollment":18},{"nctId":"NCT02965443","phase":"PHASE4","title":"Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2018-02-02","conditions":"Type 2 Diabetes","enrollment":4},{"nctId":"NCT01548651","phase":"PHASE4","title":"Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation","status":"TERMINATED","sponsor":"Baylor College of Medicine","startDate":"2012-02","conditions":"Impaired Glucose Tolerance","enrollment":8},{"nctId":"NCT04170790","phase":"NA","title":"Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-12-01","conditions":"Diabetes Mellitus, Type 2, Erectile Dysfunction With Diabetes Mellitus, Drug Interaction","enrollment":18},{"nctId":"NCT01922817","phase":"PHASE3","title":"DPP4inhibitors in Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-09","conditions":"Type 1 Diabetes, Hypoglycaemia","enrollment":28},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02613897","phase":"NA","title":"ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-01","conditions":"Diabetes Mellitus, Type 2","enrollment":56},{"nctId":"NCT03933787","phase":"EARLY_PHASE1","title":"Neuropeptide Y and Sympathovagal Balance","status":"COMPLETED","sponsor":"Eric Grouzmann","startDate":"2018-06-05","conditions":"Physical Activity, Sympathetic Nervous System, Secretion; Catecholamine","enrollment":7},{"nctId":"NCT02471404","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":939},{"nctId":"NCT02024477","phase":"PHASE4","title":"Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients","status":"COMPLETED","sponsor":"George Washington University","startDate":"2013-11","conditions":"Type 2 Diabetes","enrollment":42},{"nctId":"NCT02551874","phase":"PHASE3","title":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":650},{"nctId":"NCT02681094","phase":"PHASE3","title":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-02-26","conditions":"Type 2 Diabetes Mellitus, Inadequate Glycaemic Control","enrollment":905},{"nctId":"NCT02365233","phase":"PHASE4","title":"Fatty Liver Study in Patients With Type II Diabetes","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2013-05-01","conditions":"Type II Diabetes, Nonalcoholic Fatty Liver","enrollment":5},{"nctId":"NCT02280486","phase":"PHASE4","title":"Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":388},{"nctId":"NCT02315495","phase":"PHASE3","title":"Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes","status":"COMPLETED","sponsor":"Zilin Sun","startDate":"2015-04-03","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT02104739","phase":"PHASE4","title":"Effects of Antidiabetic Medications on the Postprandial State in Prediabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-04","conditions":"Prediabetes, Obesity","enrollment":21},{"nctId":"NCT02304081","phase":"PHASE4","title":"Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function","status":"COMPLETED","sponsor":"Prof. Dr. Thomas Forst","startDate":"2015-01","conditions":"Type2 Diabetes Mellitus","enrollment":64},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02312427","phase":"PHASE4","title":"DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Mitsui Memorial Hospital","startDate":"2015-01","conditions":"Heart Failure, Diabetes Mellitus","enrollment":10},{"nctId":"NCT02273050","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":1136},{"nctId":"NCT02588859","phase":"","title":"Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-30","conditions":"Type 2 Diabetes","enrollment":1200},{"nctId":"NCT03138356","phase":"PHASE1","title":"Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-25","conditions":"Type 2 Diabetes Mellitus","enrollment":126},{"nctId":"NCT02104804","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-07","conditions":"Type 2 Diabetes Mellitus","enrollment":953},{"nctId":"NCT02089438","phase":"PHASE4","title":"DPP-4 Inhibition, Incretins and Islet Function","status":"COMPLETED","sponsor":"Lund University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT03169959","phase":"PHASE1","title":"A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-05-29","conditions":"Type 2 Diabetes Mellitus","enrollment":85},{"nctId":"NCT02742233","phase":"PHASE4","title":"Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers","status":"UNKNOWN","sponsor":"Long Min,MD","startDate":"2015-11","conditions":"Diabetic Foot Ulcer","enrollment":60},{"nctId":"NCT01754142","phase":"","title":"Korean Post-marketing Surveillance for Kombiglyze XR®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11-24","conditions":"Diabetes Mellitus, Type 2","enrollment":755},{"nctId":"NCT01575483","phase":"","title":"Korean Post-marketing Surveillance for Onglyza®","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":3433},{"nctId":"NCT02022007","phase":"PHASE3","title":"Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","status":"COMPLETED","sponsor":"Woman's","startDate":"2014-03","conditions":"Polycystic Ovary Syndrome, Disorder of Glucose Regulation","enrollment":38},{"nctId":"NCT02182895","phase":"PHASE4","title":"Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2014-07","conditions":"Diabetes Mellitus","enrollment":72},{"nctId":"NCT01582308","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-21","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT02243176","phase":"PHASE4","title":"24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":689},{"nctId":"NCT01162876","phase":"PHASE3","title":"A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-07","conditions":"Diabetes","enrollment":20},{"nctId":"NCT00857558","phase":"PHASE2","title":"A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-01","conditions":"Diabetes, Type 2","enrollment":350},{"nctId":"NCT02765204","phase":"PHASE4","title":"A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT01192659","phase":"","title":"Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":16492},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT01782261","phase":"PHASE2","title":"Incretin Effect on the Immunological Phenotype","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2012-02","conditions":"Type 1 Diabetes","enrollment":15},{"nctId":"NCT02920801","phase":"PHASE4","title":"Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-12","conditions":"Type 2 Diabetes Mellitus","enrollment":31},{"nctId":"NCT01086280","phase":"","title":"Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01086319","phase":"","title":"Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01086306","phase":"","title":"Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01086293","phase":"","title":"Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01377935","phase":"","title":"Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01944618","phase":"","title":"forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-10","conditions":"Type 2 Diabetes","enrollment":5000},{"nctId":"NCT02307695","phase":"PHASE4","title":"The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2014-11","conditions":"Type 1 Diabetes","enrollment":184},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01768208","phase":"PHASE4","title":"Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-10","conditions":"Type 2 Diabetes","enrollment":569},{"nctId":"NCT01552005","phase":"","title":"Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus (T2D)","enrollment":1000},{"nctId":"NCT02223065","phase":"PHASE1","title":"Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":36},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02368704","phase":"","title":"Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11","conditions":"Diabetes Mellitus, Type 2, Endoplasmic Reticulum Stress","enrollment":40},{"nctId":"NCT01703637","phase":"NA","title":"Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin","status":"UNKNOWN","sponsor":"Lin Liao","startDate":"2012-10","conditions":"Type 2 Diabetes Mellitus","enrollment":300},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT01608724","phase":"PHASE4","title":"The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":2165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Onglyza"],"phase":"phase_3","status":"active","brandName":"Saxagliptin, Onglyza","genericName":"Saxagliptin, Onglyza","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}